Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Average Rating of “Hold” from Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has been assigned an average rating of “Hold” from the thirteen research firms that are currently covering the stock, Marketbeat reports. Ten analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $584.1818.

A number of analysts have recently commented on the company. TD Cowen upped their price objective on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Royal Bank Of Canada lifted their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Truist Financial upped their price target on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Finally, Barclays set a $600.00 price objective on Medpace in a report on Thursday, July 23rd.

Insider Buying and Selling at Medpace

In related news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the transaction, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 67,195 shares of company stock worth $37,989,998 in the last quarter. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Medpace

A number of hedge funds have recently made changes to their positions in MEDP. BlackRock Inc. acquired a new stake in shares of Medpace in the second quarter valued at about $1,323,047,000. AQR Capital Management LLC raised its holdings in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares during the period. Madison Asset Management LLC acquired a new position in Medpace during the 2nd quarter worth approximately $128,956,000. Arrowstreet Capital Limited Partnership lifted its position in Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares in the last quarter. Finally, American Capital Management Inc. purchased a new position in Medpace in the 2nd quarter worth approximately $111,329,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

NASDAQ MEDP opened at $578.50 on Monday. Medpace has a 12 month low of $373.00 and a 12 month high of $677.90. The company has a 50-day moving average of $536.23 and a 200-day moving average of $491.58. The company has a market cap of $16.15 billion, a P/E ratio of 33.91, a P/E/G ratio of 2.58 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the company earned $3.10 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts anticipate that Medpace will post 17.54 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.